CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

NewSpring Capital

Glenn Rieger, General Partner

The Importance of Being an Active Investor

Glenn Rieger

Glenn Rieger

How do you define your investment style?


We consider ourselves to be active investors with our growth acuity fund as very seldom we take complete control of a company. We are not a buyer firm which acquires management control and board directors but is typically a significant but minority investor.


How do you define yourself as an active investor?-It is when you talk to one of our portfolio company’s CEO years after we have made the investment and ask them who the most influential active member of your board of directors was. We trust that their answer is “person from the NewSpring is.”


We are there to help our portfolio companies both during their diligence period and after investment. We help them analyze their capital structure and optimize that between investment acuity and debt. Also, we assist them in identifying operational improvement; it could be gross margin improvement, rationalizing their cost structure to identify a commission plan for their salespeople, or identifying new and different lines of business both now and in the future.


What is your strategy to differentiate between the opportunities that you see?


At NewSpring Capital, we have a specific investment strategy that we follow which is called the “three M strategy— Management, Market, and Business Model.” There are bullets under each one of the major categories. This strategy gives all of us a common vocabulary or language to talk about one deal versus another deal. For instance, if real estate is all about location, then venture capital is all about management.


We are looking for people who have deep domain expertise, someone who is not a first time CEO. The reason being they know the gauge and routine about running these companies. The best indication for us towards a leader is the one who attracts followers (they have brought one or more people with them from other companies they used to work with).


Coming to market opportunities, we are targeting the large markets that are growing at nice rates. But these markets tend to be a fragmented market. Because the fragmentation provides a number of key advantages to us; there could be many interesting companies that we can acquire and also brings in good opportunities down the road.


And lastly, with the business model, we tend to apply quarter five forces looking for companies that have high recurring revenues, growth margin, and capital fishing paces of attracting new customers in today’s SaaS world.


Could you shed some light on your role post investment?


We typically take an active role in the audit and compensation aspect of that board which gives us a particular view of the compensation play. We look at the numbers from an audit perspective because we view that money drives results. During our diligence period which runs between 45 and 90 days, the team which is working on a particular deal will spend time thinking about how the first 90 to 120 days of the company in question would look like -things they want to make sure is in place whether it is a new CRO, commission plan, or work around the rationalization of their growth margin. We will put together specific goals and objectives that we want to accomplish in the first 90 to 120 days and then we hold ourselves accountable to that.


At NewSpring Capital, we have a specific investment strategy that we follow which is called the “three M strategy— Management, Market, and Business Model


Lastly, we refer to ourselves as a value creation team; people who are not direct employees of NewSpring but who have particular domain expertise in marketing, sales, IT infrastructure, finance, and HR. We refer them to a particular company and help that company to do better in what they are doing or help them identify opportunities.


How do you think your current portfolio of companies has benefited most from your guidance?


One such use case is, we are convinced that this industry spends far too much time thinking about just revenue growth and not on “profitable revenue growth.” And when we invested in one of our portfolio company, we commissioned all their salespeople on revenue growth. But in this particular company revenue, A had an 80 percent margin on it, and revenue B had a 40 percent margin. So, we helped that CEO to redevelop their revenue plans, so they commissioned their salespeople on margin dollars and not on revenue dollars. In the next two years, the company started selling far more of the 80 and 40 percent margin business in 18 months.


What would be the single piece of advice that you could impart to the budding entrepreneurs?


One should understand the power of social media and channel it towards their growth. Try to find a way to make a warm connection with the funding source. Use platforms such as LinkedIn to build good connections. If you are just sending a business plan, there are chances that it may get lost in the pile of emails. So if you are (someone who is trying to get on the top of the pile) thinking of making a warm introduction to NewSpring capital, anyone who relates to the company, be it an investment banker, lawyer, accountant, or insurance broker— will get you much further than just a blank call.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://biotech-startups.lifesciencesreview.com/leadership-perspective/the-importance-of-being-an-active-investor-nwid-816.html